The search for an HIV cure: Tackling latent infection

The Lancet Infectious Diseases

Volumn 13, Issue 7, 2013, Pages 614-621

  Kent, Stephen J ^a,d   Reece, Jeanette C ^a   Petravic, Janka ^b   Martyushev, Alexey ^b   Kramski, Marit ^a   De Rose, Robert ^a   Cooper, David A ^c   Kelleher, Anthony D ^c   Emery, Sean ^c   Cameron, Paul U ^d,e,f   Lewin, Sharon R ^d,e,f   Davenport, Miles P ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DISULFIRAM; HISTONE DEACETYLASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; INTERLEUKIN 7; OKT 3; PANOBINOSTAT; RALTEGRAVIR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE REGIMEN; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LONG TERMINAL REPEAT; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STABLE EXPRESSION; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; WHOLE BODY RADIATION;

BONE MARROW TRANSPLANTATION; ENZYME INHIBITORS; HIV INFECTIONS; HUMANS; HYDROXAMIC ACIDS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84879778221     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70043-4     Document Type: Review

References (97)

1. Siliciano JD, Siliciano RF The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr Opin HIV AIDS 2006, 1:121-128.
2. Chun TW, Fauci AS HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012, 26:1261-1268.
3. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
4. Schmid A, Gianella S, von Wyl V, et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One 2010, 5:e13310.
5. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012, 7:e33948.
6. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA 2012, 109:9523-9528.
7. Koelsch KK, Boesecke C, McBride K, et al. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 2011, 25:2069-2078.
8. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010, 16:460-465.
9. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009, 106:9403-9408.
10. Gandhi RT, Bosch RJ, Aga E, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010, 201:293-296.
11. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
12. Siliciano RF, Greene WC HIV latency. Cold Spring Harb Perspect Med 2012, 1:a007096.
13. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
14. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
15. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
16. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009, 15:893-900.
17. Chege D, Kovacs C, la Porte C, et al. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial. AIDS 2012, 26:167-174.
18. Allers K, Hütter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011, 117:2791-2799.
19. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360:692-698.
20. Hütter G, Thiel E Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no 2. AIDS 2011, 25:273-274.
21. Henrich TJ, Sciaranghella G, Li JZ, et al. Long-term reduction in peripheral blood HIV-1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation in two HIV-positive individuals. 19th International AIDS Conference; Washington, DC; July 22-27, 2012. THAA0101.
22. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999, 5:651-655.
23. Stellbrink HJ, van Lunzen J, Westby M, et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002, 16:1479-1487.
24. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361:1548-1559.
25. Prins JM, Jurriaans S, van Praag RM, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999, 13:2405-2410.
26. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005, 115:128-137.
27. Imamichi H, Degray G, Asmuth DM, et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 2011, 25:159-164.
28. Wightman F, Ellenberg P, Churchill M, Lewin SR HDAC inhibitors in HIV. Immunol Cell Biol 2012, 90:47-54.
29. Bosque A, Planelles V Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009, 113:58-65.
30. Saleh S, Wightman F, Ramanayake S, et al. Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology 2011, B80.
31. Fernandez G, Zeichner SL Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J 2010, 7:266.
32. Gallastegui E, Marshall B, Vidal D, et al. Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol 2012, 86:3795-3808.
33. Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 2013, 27:F7-11.
34. Xing S, Siliciano RF Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 2012, published online Dec 25. 10.1016/j.drudis.2012.12.008.
35. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485.
36. Shehu-Xhilaga M, Rhodes D, Wightman F, et al. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS 2009, 23:2047-2050.
37. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549-555.
38. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007, 195:833-836.
39. Sagot-Lerolle N, Lamine A, Chaix ML, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008, 22:1125-1129.
40. Archin NM, Cheema M, Parker D, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 2010, 5:e9390.
41. Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012, 13:291-296.
42. Xing S, Bullen CK, Shroff NS, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011, 85:6060-6064.
43. DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 2012, 4:705-710.
44. Bouchat S, Gatot JS, Kabeya K, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 2012, 26:1473-1482.
45. Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008, 26:808-816.
46. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010, 28:839-847.
47. Positive results with autologous transplant of ZFN-modified CD4 T-cells: a step toward a practical, functional cure for HIV. AIDS Patient Care STDS 2011, 25:693-695.
48. Shimizu S, Hong P, Arumugam B, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 2010, 115:1534-1544.
49. Suzuki K, Juelich T, Lim H, et al. Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region. J Biol Chem 2008, 283:23353-23363.
50. Papagno L, Alter G, Assoumou L, et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011, 25:27-36.
51. Autran B, Costagliola D, Murphy R, Katlama C Evaluating therapeutic vaccines in patients infected with HIV. Expert Rev Vaccines 2004, 3(suppl 4):S169-S177.
52. Autran B, Kinloch-de Loes S, Katlama C Therapeutic immunization in HIV infection. Curr Opin HIV AIDS 2006, 1:323-329.
53. Tubiana R, Carcelain G, Vray M, et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 2005, 23:4292-4301.
54. Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005, 192:607-617.
55. Fuller DH, Rajakumar P, Che JW, et al. Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One 2011, 7:e33715.
56. Emery S, Kelleher AD, Workman C, et al. Influence of IFNγ co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. Hum Vaccin 2007, 3:260-267.
57. García F, León A, Gatell JM, Plana M, Gallart T Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 2012, 8:569-581.
58. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501.
59. Migueles SA, Connors M Small molecules and big killers: the challenge of eliminating the latent HIV reservoir. Immunity 2012, 36:320-321.
60. Garcia F, Leon A, Gatell JM, Plana M, Gallart T Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 2012, 8:569-581.
61. De Rose R, Fernandez CS, Smith MZ, et al. Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog 2008, 4:e1000055.
62. Garcia F, Climent N, Assoumou L, et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011, 203:473-478.
63. Idoyaga J, Lubkin A, Fiorese C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA 2011, 108:2384-2389.
64. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
65. Goulder PJ, Watkins DI HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004, 4:630-640.
66. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I The utility of ADCC responses in HIV infection. Curr HIV Res 2008, 6:515-519.
67. Forthal DN, Landucci G, Daar ES Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001, 75:6953-6961.
68. Chung AW, Navis M, Isitman G, et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 2011, 58:127-131.
69. Bruunsgaard H, Pedersen C, Skinhøj P, Pedersen BK Clinical progression of HIV infection: role of NK cells. Scand J Immunol 1997, 46:91-95.
70. De Maria A, Fogli M, Costa P The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003, 33:2410-2418.
71. Geertsma MF, Stevenhagen A, van Dam EM, Nibbering PH Expression of zeta molecules is decreased in NK cells from HIV-infected patients. FEMS Immunol Med Microbiol 1999, 26:249-257.
72. Hu PF, Hultin LE, Hultin P, et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:331-340.
73. Ljunggren K, Karlson A, Fenyö EM, Jondal M Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Clin Exp Immunol 1989, 75:184-189.
74. Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci USA 2003, 100:15011-15016.
75. Sirianni MC, Mezzaromau I, Aiutiu F, Moretta A Analysis of the cytolytic activity mediated by natural killer cells from acquired immunodeficiency syndrome patients in response to phytohemagglutinin or anti-CD16 monoclonal antibody. Eur J Immunol 1994, 24:1874-1878.
76. Björkström NK, Ljunggren H-G, Sandberg JK CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol 2010, 31:401-406.
77. Johansson SE, Rollman E, Chung AW, et al. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol 2011, 24:359-368.
78. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
79. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
80. Hatano H, Jain V, Hunt PW, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2012, published online Oct 22. 10.1093/infdis/jis630.
81. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
82. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
83. Dyavar Shetty R, Velu V, Titanji K, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012, 122:1712-1716.
84. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296.
85. Tabas I, Glass CK Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013, 339:166-172.
86. Klatt NR, Harris LD, Vinton CL, et al. Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol 2010, 3:387-398.
87. Byakwaga H, Kelly M, Purcell DF, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis 2011, 204:1532-1540.
88. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011, 203:1474-1483.
89. Deeks SG HIV: how to escape treatment. Nature 2011, 477:36-37.
90. Reece J, Petravic J, Balamurali M, et al. An "escape clock" for estimating the turnover of SIV DNA in resting CD4+ T cells. PLoS Pathog 2012, 8:e1002615.
91. Murray JM, McBride K, Boesecke C, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 2012, 26:543-550.
92. Zhang L, Rowe L, He T, et al. Compartmentalization of surface envelope glycoprotein of human immunodeficiency virus type 1 during acute and chronic infection. J Virol 2002, 76:9465-9473.
93. Strain MC, Gunthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003, 100:4819-4824.
94. Persaud D, Palumbo P, Ziemniak C, et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007, 195:1402-1410.
95. Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. AIDS Res Hum Retroviruses 2007, 23:1078-1082.
96. Nowak MA, May R Virus dynamics: mathematical principles of immunology and virology 2000, Oxford University Press, Oxford.
97. Perelson AS Modelling viral and immune system dynamics. Nat Rev Immunol 2002, 2:28-36.